BI Asset Management Fondsmaeglerselskab A S Reduces Stock Holdings in Edwards Lifesciences Corporation $EW

BI Asset Management Fondsmaeglerselskab A S trimmed its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 22.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 56,187 shares of the medical research company’s stock after selling 16,432 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Edwards Lifesciences were worth $4,072,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the company. Prosperity Consulting Group LLC grew its stake in shares of Edwards Lifesciences by 3.6% during the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company’s stock worth $289,000 after acquiring an additional 134 shares during the period. Arlington Trust Co LLC lifted its holdings in Edwards Lifesciences by 1.2% during the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock valued at $804,000 after purchasing an additional 135 shares during the last quarter. Valeo Financial Advisors LLC lifted its holdings in Edwards Lifesciences by 2.8% during the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock valued at $372,000 after purchasing an additional 142 shares during the last quarter. Versant Capital Management Inc boosted its position in Edwards Lifesciences by 9.3% during the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company’s stock worth $123,000 after purchasing an additional 145 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after purchasing an additional 145 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Stifel Nicolaus upped their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, July 25th. Robert W. Baird increased their target price on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, July 25th. Citigroup reiterated a “buy” rating and issued a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Daiwa America upgraded Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Finally, Evercore ISI raised their target price on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an “in-line” rating in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $85.90.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at approximately $15,565,087. The trade was a 4.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 24,584 shares of company stock worth $1,897,762 over the last ninety days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 3.0%

EW opened at $81.2740 on Thursday. The business’s fifty day simple moving average is $77.35 and its 200 day simple moving average is $74.54. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The stock has a market cap of $47.72 billion, a PE ratio of 11.69, a P/E/G ratio of 3.81 and a beta of 1.08.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.